An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection

Liu, Tianxu; He, Qiyu; Yang, Xinyue; Li, Yuebao; Yuan, Disen; Lu, Qinghui; Tang, Tianyu; Guan, Guiwen; Zheng, Liwei; Zhang, He; Xia, Changyou; Yin, Xin; Wei, Guochao; Chen, Xiangmei; Lu, Fengmin; Wang, Lin

doi:10.1053/j.gastro.2024.03.038

Cited by 9 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HEV genotype 1 (HEV-1) and genotype 2 (HEV-2) primarily infect humans, and are predominantly circulating in developing countries, particularly in Asia and Africa, often related to large waterborne outbreaks [ 7 , 8 ]. Recently, a study found that HEV-1 can also experimentally infect Mongolian gerbils [ 9 ]. While genotype 3 (HEV-3) and genotype 4 (HEV-4) infect mammals but occasionally transmit to humans, and are prevalent in industrialized and high-income countries [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China

Huang,

Zheng,

Chen

et al. 2024

Emerging Microbes & Infections

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is an important cause of acute hepatitis, however, is highly neglected and largely underreported. This study aimed to describe the detailed epidemiology of hepatitis E (HE) through a 10-year surveillance. A community-based active hepatitis surveillance was conducted between November 2007 and October 2017 in 11 townships of Dongtai City in China, involving 355,673 residents. Serum samples were obtained from patients presenting with hepatitis symptoms for more than 3 days. Serum alanine aminotransferase (ALT) levels greater than 2.5 times the upper limit of normal (ULN) were considered acute hepatitis. Samples were subsequently tested for IgG and IgM anti-HEV antibodies, HEV RNA, and hepatitis B surface antigen (HBsAg). The data indicated the incidence of HE fluctuated downward from 2007 to 2017, with an average annual age-standardized incidence of 17.50 per 100,000, exceeding the 10.26 per 100,000 in the National Notifiable Disease Report System (NNDRS). The incidence was notably higher among males (20.95 per 100,000) and individuals aged 50–69 years (37.47 per 100,000). Genotype 4 (HEV-4) was the predominantly circulating genotype during the study period. Furthermore, the study revealed the incidence of hepatitis with HEV and hepatitis B virus (HBV) co-infection was 4.99 per 100,000. The active surveillance system identified a higher incidence of HE compared to NNDRS, with a decreased prevalence over a 10-year period. While efforts are still needed to prevent HE in high-risk populations, including individuals with hepatitis B and the elderly.

show abstract

Section: Introductionmentioning

confidence: 99%

Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China

Huang,

Zheng,

Chen

et al. 2024

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing

Fan,

Xu,

Cao

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis E virus (HEV) poses a serious threat to both public health and animal food safety, thereby highlighting the demands for rapid, sensitive, and easy‐to‐use detection. This study aimed to develop a One‐Pot assay using CRISPR/Cas13a for detecting HEV RNA, suitable for point‐of‐care testing (POCT) in resource‐limited settings. CRISPR/Cas13a combined with reverse transcription polymerase chain reaction (RT‐PCR) and reverse transcription recombinase‐aided amplification (RT‐RAA) was applied to a One‐Pot assay device. Additionally, a large cohort of HEV‐infected patient (154) and animal (104) specimens was utilized for validation. The RT‐PCR/RT‐RAA + CRISPR/Cas13a assays for HEV RNA detection (genotypes: HEV‐1, HEV‐3, and HEV‐4) were established, optimized, and validated, achieving a limit of detection (LoD) of 1 copy/μL and 100% specificity. In the application validation for HEV infection, the positive rates of the RT‐PCR + CRISPR and RT‐RAA + CRISPR assays were 98.6% and 89.6% for patients, and 96.6% and 88.8% for animals, respectively, which were superior to those of RT‐qPCR. Furthermore, sample rapid lysis, reagent lyophilization, and the One‐Pot device were integrated to construct a One‐Pot assay with an LoD of 102 copies/μL. Despite slight decreases in sensitivity, the One‐Pot assay significantly reduces the assay time to 35 min, making it easy to perform, minimizing contamination, and meeting the requirements for screening. We developed a One‐Pot assay of HEV RNA using the CRISPR/Cas13a which effectively realizes a POCT test and maximizes the impetus for POCT implementation and shows potential as a valuable tool for detecting and monitoring HEV infection.

show abstract

Hepatitis E virus infection during pregnancy: Advances in animal models

Li,

Wang,

Wan

et al. 2024

Research in Veterinary Science

View full text Add to dashboard Cite

An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection

Cited by 9 publications

References 54 publications

Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China

Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China

One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing

Hepatitis E virus infection during pregnancy: Advances in animal models

Contact Info

Product

Resources

About